Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jamie Lynch

Sports Medicine San Antonio, TX Medical Doctor

NPI 1053577882 CMS profile 649687

18626 Hardy Oak Blvd Ste 101, San Antonio, TX 78258

Open in the dashboard

General payments

$109,329

204 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jamie Lynch of San Antonio, TX is reported in the CMS Open Payments database as having received $109,329 across 204 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $31,270 49
2024 General $31,754 38
2023 General $33,976 59
2022 General $6,289 17
2021 General $1,036 16
2020 General $2,293 7
2019 General $2,710 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jamie Lynch
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Jamie Lynch were reported at $31,270. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Jamie Lynch Sports Medicine median Middle half National median
2019 $2,710 $1,176 $199–$4,249 $163
2020 $2,293 $708 $96–$2,890 $114
2021 $1,036 $1,213 $152–$3,994 $132
2022 $6,289 $1,230 $159–$3,998 $149
2023 $33,976 $584 $146–$2,836 $160
2024 $31,754 $628 $163–$3,168 $164
2025 $31,270 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $74,216 90 payments
  2. Catalyst OrthoScience $9,116 9 payments
  3. Medical Device Business Services, Inc. $7,359 16 payments
  4. DePuy Synthes Products, Inc. $6,566 5 payments
  5. Encore Medical, LP $3,226 6 payments
  6. Medinc of Texas $2,789 3 payments
  7. Musculoskeletal Transplant Foundation Inc. $1,872 11 payments
  8. Moximed, Inc $1,131 3 payments
  9. KCI USA, Inc $400 1 payment
  10. Arthrex, Inc. $358 5 payments
  11. Other $2,294 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $79,911 21 payments
  2. Travel and Lodging $19,535 59 payments
  3. Food and Beverage $7,094 121 payments
  4. Education $2,789 3 payments
Products named General payments · program years 2019–2025
  1. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $55,519 68 payments
  2. AEQUALIS ASCEND FLEX $19,829 7 payments
  3. TORNIER PERFORM REVERSED AUGMENTED GLENOID $15,831 3 payments
  4. TORNIER PERFORM ANATOMIC AUGMENTED GLENOID $15,831 3 payments
  5. TORNIER PERFORM REVERSED GLENOID $15,831 3 payments
  6. AEQUALIS PERFORM $10,939 5 payments
  7. AEQUALIS REVERSED II $9,596 3 payments
  8. Catalyst Total CSR $8,743 5 payments
  9. DYNACORD $5,881 7 payments
  10. MONOVISC $5,531 6 payments
  11. Other $14,160 107 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

46

Median for Orthopaedic Surgery: 30

Drug cost

$143

Median for Orthopaedic Surgery: $176

Branded share of claims

0%

Median for Orthopaedic Surgery: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tizanidine Hcl Generic 24 $80
Gabapentin Generic 22 $62

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,233 Part D prescribers listed as Orthopaedic Surgery; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilretta
  • Pacira Pharmaceuticals Incorporated $5
$5 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $5
$5 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

204 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record